PDCD1 and diabetes mellitus: Stamatouli et al. measured diabetes autoantibodies (glutamic and decarboxylase 65 antibodies, islet antigen 2 antibodies, and insulin autoantibodies) in solid cancer patients treated with anti-PD-1 or anti-PD-L1 antibodies, and found that patients positive for type 1 diabetes antibodies at the time of presentation developed diabetes-related irAEs after fewer cycles than those without autoantibodies (158).